Guru Subramanian Guru Murthy

10PUBLICATIONS
48CO-AUTHORS
Haematological tumoursRegenerative medicine (incl. stem cells)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 15, 2026
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

|Aug 31, 2026
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

|Jul 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

|Feb 15, 2025
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Sameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani

|Jan 25, 2024
Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation.

Guru Subramanian Guru Murthy, Tao Zhang, Yung-Tsi Bolon

|Feb 22, 2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Talha Badar, Ehab Atallah, Rory Shallis

Pageof 2

Frequent Collaborators

5 joint publications

Talha Badar

4 joint publications

Anand Patel

3 joint publications

Jan P Bewersdorf

3 joint publications

Madelyn Burkart